How should a 50-year-old man with a serum testosterone of 245 ng/dL be evaluated and managed?

Management of a 50-Year-Old Male with Testosterone Level of 245 ng/dL

This patient requires confirmatory testing with a second early morning testosterone level, assessment for hypogonadal symptoms, and evaluation for underlying causes before considering testosterone therapy.

Initial Diagnostic Approach

A testosterone level of 245 ng/dL falls below the typical diagnostic threshold of 300 ng/dL used in most guidelines 1, 2. However, a single low value is insufficient for diagnosis.

Required Confirmatory Testing

• Obtain a second early morning (7-11 AM) total testosterone level to confirm persistent low testosterone 2
• Both values should be measured using a reliable assay
• The diagnosis of testosterone deficiency requires both biochemically low testosterone AND clinical symptoms 1, 3

Essential Clinical Assessment

Specifically evaluate for these hypogonadal symptoms:

• Sexual dysfunction: decreased libido, erectile dysfunction, reduced frequency of morning erections
• Physical changes: decreased muscle mass and strength, increased body fat (particularly abdominal), reduced bone density or history of low-trauma fractures
• Metabolic symptoms: fatigue, decreased energy, mood changes
• Associated conditions: diabetes, metabolic syndrome, osteoporosis 3, 4

Exclude Secondary Causes

Before diagnosing age-related hypogonadism, rule out:

• Pituitary disorders: measure LH and FSH (normal levels with low testosterone suggest late-onset hypogonadism)
• Medications: opioids, glucocorticoids
• Systemic illness: chronic kidney disease, liver disease, HIV
• Obesity and sleep apnea: both can suppress testosterone
• Testicular pathology: examine for masses or atrophy 1, 5

Treatment Decision Algorithm

If Confirmed Low Testosterone (<300 ng/dL on two occasions) WITH Symptoms:

Consider testosterone therapy with the following approach 1, 2:

1. Pre-treatment screening (mandatory):

   • Digital rectal examination and PSA (at age 50, baseline PSA should be checked) 2
   • Hematocrit (contraindicated if >50%, relative contraindication if >54%) 2
   • Screen for prostate cancer risk factors
   • Assess for contraindications: active prostate or breast cancer, untreated severe sleep apnea, uncontrolled heart failure 6

2. Initiate therapy if no contraindications exist:

   • Goal: raise testosterone to mid-normal range (450-600 ng/dL) 1, 2, 3
   • Intramuscular testosterone (enanthate or cypionate) is preferred over transdermal formulations due to significantly lower cost with similar efficacy and safety 7
   • Alternative: transdermal gel if patient preference or injection intolerance

3. Trial period approach:

   • Reassess at 3 months for symptom improvement and adverse effects 1, 2
   • Discontinue if no improvement in symptoms within 12 months 7
   • Measure testosterone level at 3 months to ensure mid-normal range achieved 2

If Confirmed Low Testosterone WITHOUT Symptoms:

Do not initiate testosterone therapy 1, 7. The evidence does not support treating asymptomatic men with low testosterone, and the American College of Physicians explicitly recommends against this practice 7.

If Borderline Testosterone (245-300 ng/dL) WITH Symptoms:

This represents a gray zone. A 3-month therapeutic trial can be considered in symptomatic men after thorough discussion of uncertain benefits and potential risks 5. This decision should only be made by experienced clinicians.

Monitoring Protocol if Treatment Initiated

At 3 months 2:

• Assess symptom response (particularly sexual function)
• Check testosterone level (adjust dose if <400 or >700 ng/dL)
• Measure hematocrit (stop if >54%)
• Check PSA and perform digital rectal examination

Annually thereafter 2:

• Symptom assessment
• Hematocrit monitoring
• PSA and digital rectal examination
• Consider bone density at 1-2 years if osteoporosis or fracture history present

Discontinue therapy if 2:

• PSA increases >1.4 ng/mL in any 12-month period
• PSA velocity >0.4 ng/mL/year after 6 months of treatment
• Hematocrit >54%
• No symptom improvement after 12 months 7

Critical Caveats

Important nuances in this case:

The 2010 Endocrine Society guidelines 2 support testosterone therapy for symptomatic men with unequivocally low testosterone, while the 2020 American College of Physicians guidelines 8, 7 are more restrictive, recommending therapy only for sexual dysfunction and explicitly recommending against treatment for energy, vitality, physical function, or cognition. The ACP guidelines represent the most recent high-quality evidence and should guide practice when symptoms are non-sexual 7.

The evidence for cardiovascular safety remains uncertain with limited long-term data 8. Recent evidence suggests testosterone therapy does not increase major cardiovascular events, but trials lack adequate power for definitive conclusions 8, 3.

At age 50, this patient is younger than most trial participants (typically ≥60 years), which limits direct applicability of evidence but also suggests potentially longer treatment duration if initiated 8.